Covid-19 roundup: Mesoblast takes another hit as FDA demands additional trial ahead of any EUA review
September 1, 2021
Shares of Mesoblast $MESO tumbled 12% on Tuesday after the small Australian biotech reported that the FDA is demanding another trial before the agency will consider an emergency authorization for their experimental drug remestemcel-L for Covid patients suffering from acute respiratory distress syndrome.
Read the source article at endpts.com
2021-09-01 11:11:33